



**CAVA HEALTHCARE INC.**  
**(FORMERLY ALTERNATIVE EXTRACTS INC.)**  
**PRESS RELEASE**

**CAVA HEALTHCARE INC. ANNOUNCES THE ACQUISITION OF A PORTFOLIO OF PATENTS AND THE OPENING OF A PRIVATE PLACEMENT**

**Vancouver, British Columbia, July 9, 2019** – Çava Healthcare Inc. (the “**Company**”) is pleased to announce that it has entered into an agreement (the “**Agreement**”) with multiple inventors, including Professor Raymond Andersen and Professor Wilf Jefferies of the University of British Columbia (Vancouver) and Professor Dara Dickstein of the Uniformed Services University of the Health Sciences (Washington, DC), to acquire a portfolio of five patent families comprised of patents and patent applications filed worldwide. Under the Agreement, the Company will acquire 100% of the legal and beneficial interest in the patents as summarized in the Company’s financial reporting. The patent portfolio relates to translating new therapies and biomarkers for disease in the areas of Tumour Immunology and Cancer Immunotherapy; Alzheimer’s disease and the Blood Brain Barrier; and Sepsis and Inflammation.

The following is a summary of the five patent families acquired by the Company:

- (1) **A New Biomarker for Diagnosing Cancer:** This biomarker technology has completed two clinical trials in cancer patients that demonstrate it has the potential to be used as a cancer diagnostic and predictor for cancer outcome.
- (2) **Histone Deacetylase Inhibitor (HDACi) for use in the Treatment of Cancer:** HDACi alters epigenetic programs in cancer cells and may be utilized to reduce cancer growth by enhancing the immune response against tumours.
- (3) **Natural Compounds that Increase Immune Responses Against Cancer:** Natural products and their improved synthetic analogs, that are biosimilar to cannabinoids, may be used to harness the power of the immune system to recognize and destroy cancers.
- (4) **A Method to Reduce Inflammation in Chronic and Acute disease:** The technology describes a novel immune regulator that is a missing link between inflammation and resolution of inflammation in sepsis.
- (5) **A Novel Approach to Treat Alzheimer’s Disease:** Current therapies for the treatment of Alzheimer’s disease focussed on targeting amyloid beta and tau proteins have been unsuccessful in clinical trials. As such, new drug targets and novel approaches are necessary. This intellectual property describes the invention of a novel therapeutic approach for treating Alzheimer’s disease. It has been validated in preclinical animal models of Alzheimer’s disease.

Mr. Samuel Mercer, BSc, CEO and Director commented, “The acquisition of this valuable portfolio of patents and patent applications provide immense potential for the Company to develop and produce medicinal-plant-derived extracts of high quality for industrial customers, via advanced extraction and production capabilities, and to also advance the development of a unique set of pharmaceutical medicinal candidates through preclinical and clinical trials. The Company’s candidates that are under development, now range widely to include plant-derived health supplements and ingredients, bioceuticals, plant-derived pharmaceutical candidates, repurposed existing drug candidates for new indications, and biomarkers for cancer diagnosis.”

**Private Placement:** The Company is also pleased to announce that it has arranged private placements (the "Private Placement") of up to 2,000,000 units (each, a "Unit"), at a price of \$0.25 per Unit, for gross proceeds of up to \$500,000. Each Unit is comprised of one common share (a "Share") of the Company and one common share purchase warrant (a "Warrant") exercisable at \$0.40 per Share. Each Warrant shall entitle the holder to purchase one additional Share at any time on or before 5:00 p.m. (Vancouver time) on or before the first anniversary of the date of issuance of the Warrants; except that, if over a period of 10 consecutive trading days from the date that is 4 months and a day from the date of issuance of the Warrants until 30 days prior to the date that the Warrants would otherwise expire, the closing price of the Company's common shares on a stock exchange (if the common shares are listed) is or exceeds \$0.50, then the Company may, at its option, provide written notice to the warrant holders to exercise their Warrants within 30 days of the date of the notice, failing which the Warrants will expire.

The funds will be used for general working capital, product development and distribution.

Finders' fees shall be paid in cash, subject to the Board approval and in accordance with the policies of the regulating authority.

For further information, contact the Company at [info@cavahealthcare.com](mailto:info@cavahealthcare.com) or (604) 803-8439.

On behalf of the Board,

Mr. Samuel Mercer, BSc, CEO and Director

## **ÇAVA HEALTHCARE INC.**

### **ÇAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE**

Chronic and acute inflammation and poor immune function are at the core of many diseases. ÇAVA is addressing this unmet healthcare challenge through isolation and characterization of novel medically useful compounds from plants, development and validation of novel biomarkers for disease, and application of cutting-edge technologies to reverse inflammation and restore immune function to achieve optimal health.

#### **FORWARD LOOKING INFORMATION**

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on [www.sedar.com](http://www.sedar.com).

